Literature DB >> 8570663

Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines.

P J Murray1, A Aldovini, R A Young.   

Abstract

Bacille Calmette-Guérin (BCG) is a live, attenuated strain of Mycobacterium bovis used widely for tuberculosis prophylaxis and bladder cancer immunotherapy, although it has limitations in both contexts. To investigate whether BCG's immunostimulatory properties could be modified, and to gain insight into the interaction between mycobacteria and their hosts, we constructed recombinant BCG strains that secrete functional murine cytokines and studied their properties in mouse models of experimental infection. Cell-mediated immune responses to mycobacterial antigen (purified protein derivative) were assayed using splenocytes from mice inoculated with various BCG recombinants. Antigen-specific proliferation and cytokine release were found to be substantially greater with splenocytes derived from mice injected with cytokine-secreting BCG than with splenocytes from mice injected with BCG lacking cytokines. The most profound effects were induced by BCG secreting interleukin 2, interferon gamma, or granulocyte-macrophage colony-stimulating factor. Thus, cytokine-secreting BCG can enhance immune responses to mycobacterial antigens and may be improved reagents for tuberculosis prophylaxis and cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8570663      PMCID: PMC40162          DOI: 10.1073/pnas.93.2.934

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

Review 1.  The BCG story: lessons from the past and implications for the future.

Authors:  P E Fine
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr

2.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

3.  BCG vaccination.

Authors:  F Luelmo
Journal:  Am Rev Respir Dis       Date:  1982-03

4.  Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.

Authors:  A Aldovini; R A Young
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells.

Authors:  C P Chiu; C Moulds; R L Coffman; D Rennick; F Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

6.  Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes.

Authors:  M A O'Donnell; A Aldovini; R B Duda; H Yang; A Szilvasi; R A Young; W C DeWolf
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

7.  Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice.

Authors:  P Gros; E Skamene; A Forget
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

8.  Differences in response among inbred mouse strains to infection with small doses of Mycobacterium bovis BCG.

Authors:  A Forget; E Skamene; P Gros; A C Miailhe; R Turcotte
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

9.  Secretion of human interleukin 2 by recombinant Mycobacterium bovis BCG.

Authors:  D Kong; D Y Kunimoto
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

10.  Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha.

Authors:  I E Flesch; J H Hess; S Huang; M Aguet; J Rothe; H Bluethmann; S H Kaufmann
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  46 in total

1.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

2.  A role for tumour necrosis factor-alpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6'-dimycolate induced granulomatous response.

Authors:  Kerry J Welsh; April N Abbott; Shen-An Hwang; Jessica Indrigo; Lisa Y Armitige; Michael R Blackburn; Robert L Hunter; Jeffrey K Actor
Journal:  Microbiology (Reading)       Date:  2008-06       Impact factor: 2.777

3.  A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

Authors:  Daniel F Hoft; Azra Blazevic; Getahun Abate; Willem A Hanekom; Gilla Kaplan; Jorge H Soler; Frank Weichold; Larry Geiter; Jerald C Sadoff; Marcus A Horwitz
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

4.  Designing a vaccine for tuberculosis.

Authors:  A S Malin; D B Young
Journal:  BMJ       Date:  1996-06-15

5.  Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes.

Authors:  J Hess; D Miko; A Catic; V Lehmensiek; D G Russell; S H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

6.  New age adjuvants and delivery systems for subunit vaccines.

Authors:  S Kurella; M Manocha; L Sabhnani; B Thomas; D N Rao
Journal:  Indian J Clin Biochem       Date:  2000-08

7.  The tuberculosis epidemic. Scientific challenges and opportunities.

Authors:  A M Ginsberg
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

8.  Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection.

Authors:  Anthony A Ryan; Joanne M Spratt; Warwick J Britton; James A Triccas
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

Review 9.  Synthetic biology approaches in drug discovery and pharmaceutical biotechnology.

Authors:  Heinz Neumann; Petra Neumann-Staubitz
Journal:  Appl Microbiol Biotechnol       Date:  2010-04-16       Impact factor: 4.813

10.  Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model.

Authors:  Rajpal S Kashyap; Aliabbas A Husain; Shweta H Morey; Milind S Panchbhai; Poonam S Deshpande; Hemant J Purohit; Girdhar M Taori; Hatim F Daginawala
Journal:  J Immune Based Ther Vaccines       Date:  2010-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.